The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
IRT 3.2.0 acquires new models and extended annotations
(Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
InSysBio is glad to present Cytocon DB 1.2.6.6! Cytocon DB team has reviewed 39 articles to introduce new data. It should be outlined that the total number of concentrations within the Database has already exceeded 10 thousand!
InSysBio has received a new set of results in framework of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.
First
Prev